Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

February 29, 2024

Conditions
Colorectal Cancer
Interventions
PROCEDURE

HAIC

After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.

DRUG

Fruquintinib

3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC

DRUG

Tislelizumab

200mg, ivgtt, d1, 21 days for a cycle

DRUG

Raltitrexed

2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles

DRUG

Oxaliplatin

85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles

DRUG

Irinotecan

120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles

Trial Locations (1)

200062

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER